Optimer synthetic binders for swine vaccine adjuvants

Overview

Optimer synthetic binders are antibody-like molecules that can be incorporated into vaccines as adjuvants (substances added to improve immune response). Aptamer Group plc has entered a global licensing agreement with the University of Glasgow for the commercial use of a developed panel of Optimer binders as vaccine adjuvants in the swine health sector. The University of Glasgow will lead product development, with commercialization anticipated within the next 12 months, creating an actionable route for swine vaccine developers to assess licensing, co-development, or field validation for improved immune response and pig health outcomes.

Technical specifications

• Licensed asset: a developed panel of Optimer binders for use as vaccine adjuvants in vaccine development for pigs [1][3]
• Product owner for development: University of Glasgow holds exclusive rights for use in vaccine development and leads product development [1][3]
• Evidence base: Optimer binders have demonstrated strong immune-enhancing capabilities in preclinical studies led by the University of Glasgow [1][6]
• Commercial structure: royalty to Aptamer on downstream sales of Optimer-containing vaccines (10% royalty mentioned in the agreement disclosures) [1][3]

Limitations: The available sources describe preclinical performance and the licensing/commercialization timeline, but do not provide specific binder sequences, dosing, formulation details, or regulatory status beyond the planned commercialization window.

Technology readiness level

Commercialization is anticipated within the next 12 months under University-led product development following a licensing agreement and preclinical performance demonstrating immune enhancement [1][3][6]. This supports an “in development / close to deployment” assessment. Technology readiness level: 6.